A team of researchers at Karolinska Institutet has developed a novel tool for genetic research. The study, published in ...

A new study has uncovered a molecular mechanism by which rice cells perceive viral infections and initiate antiviral response ...

Japanese researchers used a nonviral piggyBac system to genetically modify cynomolgus monkeys, enabling more accurate disease ...

MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

Though recent discoveries have revealed how rice plants mitigate such threats by initiating immune responses against ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

A groundbreaking study led by Li Yi, professor at the School of Life Sciences, was published in Nature on March 12, titled "Perception of viral ...

COVID-19 not only advanced scientific boundaries, but also transformed research methodologies and accelerated adaptive ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

The Adeno Associated Virus Vector Manufacturing market, valued at USD 1,148.4 million in 2024, is expected to register robust revenue CAGR of 19.6%.Request free copy of this report:  March 14, 2025 - ...

The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.